Key Long-acting Beta-agonists Market Players:
- GlaxoSmithKline plc (GSK)
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- AstraZeneca plc
- Boehringer Ingelheim
- Novartis AG
- Mylan N.V. (Viatris Inc.)
- Teva Pharmaceutical Industries
- Chiesi Farmaceutici S.p.A.
- Cipla Ltd.
- Sun Pharmaceutical Industries Ltd.
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company
- Zambon S.p.A.
- Orion Corporation
- Glenmark Pharmaceuticals
- SK Bioscience Co., Ltd.
- Samsung Biologics
- Lupin Limited
- CSL Limited (Seqirus)
- Bio-pharma Sdn Bhd
- Neopharma
The worldwide market is extremely competitive with the presence of both regional and multinational organizations. Notable firms, including Novartis, GSK, Boehringer Ingelheim, and AstraZeneca, are readily controlling the overall market by branded segment share through combination therapies and long-acting inhalers. Besides, firms from South Korea and India are increasingly gaining attention, owing to affordable generic alternatives as well as API exports, particularly in developing nations. Meanwhile, strategies, including Mylan’s successful merger into Viatris, Samsung Biologics’ partnerships, and Cipla’s EU expansion, are surging competition in the market.
Here is a list of key players operating in the market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of long-acting beta-agonists is evaluated at USD 11.3 billion.
The long-acting beta-agonists market size was USD 11.3 billion in 2025 and is anticipated to reach USD 17.9 billion by the end of 2035, increasing at a CAGR of 5.3% during the forecast period, i.e., 2026-2035.
North America in the long-acting beta-agonists market is projected to garner the largest share of 40.3% by the end of 2035.
The major players in the market are GlaxoSmithKline plc (GSK), AstraZeneca plc, Boehringer Ingelheim, Novartis AG, Mylan N.V. (Viatris Inc.), Teva Pharmaceutical Industries, Chiesi Farmaceutici S.p.A., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Astellas Pharma Inc., Takeda Pharmaceutical Company, Zambon S.p.A., Orion Corporation, Glenmark Pharmaceuticals, SK Bioscience Co., Ltd., Samsung Biologics, Lupin Limited, CSL Limited (Seqirus), Bio-pharma Sdn Bhd, Neopharma.
